CANCERS BRONCHIQUES NON A PETITES CELLULES: Stades I-III initialement résécables |
|
Synonymes de chimiothérapie d'induction : chimiothérapie première, néoadjuvante ou protoadjuvante
|
Référence |
Traitement |
n pts |
IIIA |
N2 |
T3 |
T3 N0-1 |
RO |
SM (mois) |
p |
|
Pass, 1992(1) |
1.
CDDP-VP16 |
13 |
13 |
13 |
0 |
0 |
62
% |
29 |
NS |
|
2. Contrôle |
14 |
14 |
14 |
0 |
0 |
- |
16 |
||
|
Rosell, 1994(2;3) |
1. MMC-Ifo-CDDP(3x) puis chirurgie (+RT) |
30 |
26 |
25 |
13 |
5 |
53% |
26 |
S |
|
2. chirurgie (+RT) |
30 |
21 |
19 |
16 |
11 |
- |
8 |
||
|
Roth, 1994(4;5) |
1. CPA-VP16- CDDP(6x) puis chirurgie (+RT si incomplet) |
29 |
20 |
20 |
12 |
6 |
35% |
64 |
S |
|
2. chirurgie (+RT si incomplet) |
32 |
24 |
22 |
15 |
10 |
- |
11 |
||
|
Depierre, 2001(6) |
1. MMC-Ifo-CDDP x 2 puis chirurgie |
179 |
92 |
72 |
29 |
|
64 % |
37 |
0.15 * |
|
2. Chirurgie |
176 |
75 |
50 |
29 |
|
- |
26 |
||
|
Nagai, 2003 (7) |
1. CDDP-VDS (3x) puis chirurgie |
31 |
31 |
31 |
3 |
0 |
28% |
17 |
NS |
|
2. Chirurgie |
31 |
31 |
31 |
3 |
0 |
77% |
16 |
||
|
Gilligan, 2007
(8) |
1. 3 x chimio à base platine puis Chirurgie |
258 |
7 % |
|
|
|
81 % |
|
0,86 |
|
2. Chirurgie |
261 |
6 % |
|
|
|
79 % |
|
||
|
Kunitoh, 2008 (9) |
1. Cisplatine + docétaxel x 2 puis chirurgie |
40 |
0 |
0 |
4 |
|
98 % |
75 % à 4 ans |
|
|
2. Docétaxel (x2) puis chirurgie |
39 |
0 |
0 |
4 |
|
95 % |
57 % à 4 ans |
||
|
Pisters, 2010
(10) |
1. Chirurgie |
174 |
|
|
|
|
41 % |
41 % à 5 ans |
0,11 |
|
2. Carbo-paclitaxel x 3 puis chirurgie |
180 |
|
|
|
|
|
50 % à 5 ans |
||
|
Scagliotti, 2012 (11), I |
1. Chirurgie |
141 |
3 |
1 |
|
|
35% |
4,8 ans |
0,04 |
|
2. 3x CDDP-gemci puis chirurgie |
129 |
6 |
0 |
|
|
|
7,8 ans |
||
|
Berghmans, 2012 (12) |
1. CDDP-Ifo-MMC 3 x puis chirurgie |
69 |
21 |
|
|
|
77 % |
|
NS |
|
2. CDDP- gemci- VNR 3x puis chirurgie |
71 |
23 |
|
|
|
80 % |
|
* S en cas de stades N0-N1
Références
(1) Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53(6):992-998.
(2) Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330(3):153-158.
(3) Rosell R, Gomez-Codina J, Camps C, Javier SJ, Maestre J, Padilla J et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26(1):7-14.
(4) Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JBJ, Lee JS et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86(9):673-680.
(5) Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette RM, Putnam JBJ et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21(1):1-6.
(6) Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B et al. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer. J Clin Oncol 2002; 20(1):247-253.
(7) Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125(2):254-260.
(8) Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007 Jun 9;369(9577):1929-37
(9) Kunitoh H, Kato H, Tsuboi M, Asamura H, Tada H, Nagai K, et al. A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer 2008 Aug 26; 99 : 852-7.
(10) Pisters KM, Vallieres E, Crowley JJ, Franklin WA, Bunn PA, Jr., Ginsberg RJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010 Apr 10;28(11):1843-9
(11) Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, et al. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J Clin Oncol 2012 Jan 10;30(2):172-8.
(12) Berghmans T, Lafitte JJ, Giner V, Berchier MC, Scherpereel A, Lewin D, et al. Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working Party. Lung Cancer 2012 Sep;77(3):605-10.